Erschienen in:
01.09.2012 | Original Paper
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)
verfasst von:
Peter H. Wiernik, Zhuoxin Sun, Holly Gundacker, Gordon Dewald, Marilyn L. Slovak, Elisabeth Paietta, Haesook T. Kim, Frederick R. Appelbaum, Peter A. Cassileth, Martin S. Tallman
Erschienen in:
Medical Oncology
|
Ausgabe 3/2012
Einloggen, um Zugang zu erhalten
Abstract
This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or all-trans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.